This story has been corrected to clarify that Compugen received orders from [email protected] and not Protogene.
NEW YORK, Dec 1 – Compugen said Friday it had received orders from Pfizer and [email protected] of Germany for its Z3 proteomics software and expects to announce several more commercial users in the near future.
“Several pharmas are acquiring the product and we expect that by the end of the year we will have six or seven clients,” Lior Ma’ayan, vice president of commercial operations at Compugen, told GenomeWeb.
Ma’ayan said an Australian proteomics association had also signed on for the Z3 software, adding that he expected to announce the names of two American pharmaceutical customers within the next 10 days.
Z3, which was released commercially in September, is designed to automatically and instantaneously align proteins from healthy and diseased tissue, allowing scientists to quickly hone in on protein variations.
The company charges $29,000 per one-year license. Some deals for the product totaled hundreds of thousands of dollars, Ma’ayan said.
He added that the company was also beta-testing a web solution for the Z3 product, which would allow users to load 2-D gels on the web and have them evaluated by Compugen’s scientists through its LabOnWeb portal.
Ma’ayan noted that the company still had to determine the price for the web-based service, adding that the on-line service might prove more expensive than the software since Compugen’s experts would be evaluating the samples.
Earlier this week, Motorola announced that it had agreed to use Compugen’s chip design services in the development and manufacture of some of its DNA biochips.